% | $
Quotes you view appear here for quick access.

Pluristem Therapeutics, Inc. Message Board

  • immunocell immunocell Nov 2, 2011 9:44 AM Flag

    fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis

    1. Stem Cells. 2008 Oct;26(10):2625-33. Epub 2008 Jul 31.

    Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces
    therapeutic angiogenesis in a rat model of hind limb ischemia.

    Ishikane S, Ohnishi S, Yamahara K, Sada M, Harada K, Mishima K, Iwasaki K,
    Fujiwara M, Kitamura S, Nagaya N, Ikeda T.

    Department of Perinatology, National Cardiovascular Center Research Institute,
    Suita, Osaka, Japan.

    Bone marrow-derived mesenchymal stem cells (BM-MSC) have been demonstrated to be
    an attractive therapeutic cell source for tissue regeneration and repair.
    However, it remains unknown whether or not allogeneic transplantation of
    mesenchymal stem cells (MSC) derived from fetal membranes (FM), which are
    generally discarded as medical waste after delivery, has therapeutic potential.
    FM-MSC were obtained from Lewis rats and had surface antigen expression and
    multipotent potential partly similar to those of BM-MSC. Compared with BM-MSC,
    FM-MSC secreted a comparable amount of hepatocyte growth factor despite a small
    amount of vascular endothelial growth factor. FM-MSC and BM-MSC both expressed
    major histocompatibility complex (MHC) class I but not MHC class II antigens and
    did not elicit allogeneic lymphocyte proliferation in mixed lymphocyte culture.
    FM-MSC or BM-MSC obtained from Lewis rats were injected into a MHC-mismatched
    August-Copenhagen-Irish rat model of hind limb ischemia. Three weeks after
    injection, blood perfusion and capillary density were significantly higher in the
    FM-MSC and BM-MSC groups than in the phosphate-buffered saline group, and
    allogeneic FM-MSC and BM-MSC were still observed. In nonischemic hind limb
    tissues, allogeneic FM-MSC and BM-MSC injection were associated with a
    comparatively small amount of T lymphocyte infiltration, compared with the
    injection of allogeneic splenic lymphocytes. In conclusion, allogeneic FM-MSC
    injection did not elicit a lymphocyte proliferative response and provided
    significant improvement in a rat model of hind limb ischemia, comparable to the
    response to BM-MSC. Thus, allogeneic injection of FM-MSC may be a new therapeutic
    strategy for the treatment of severe peripheral vascular disease. Disclosure of
    potential conflicts of interest is found at the end of this article.

    PMID: 18669910 [PubMed - indexed for MEDLINE]

2.730.00(0.00%)Jun 2 3:59 PMEDT